Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 6.0 %

NYSE:BTX opened at $0.42 on Friday. The stock has a 50 day moving average of $0.44 and a two-hundred day moving average of $1.11. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The firm has a market cap of $24.84 million, a P/E ratio of -0.19 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.